Progress with the times
Release time:
2020-08-14
Progress with the Times
In fact, many clips from the movie "Great, My Country" appeared in the documentary series "Brilliant China" broadcast by CCTV9 . When I watch TV, I feel that China is really powerful, and the rapid development of science and technology has exceeded my imagination. I can't help feeling that "the motherland is so big, I am so small. The film uses more exciting pictures to fully demonstrate China's style and strength. Walking out of the cinema, all that came to my mind were the Hong Kong-Zhuhai-Macao Bridge, Bridge Project, Yangshan Deepwater Port, Jiaolong, FAST Tianyan Project, Fuxing EMU, Quantum Science, Tibetan Antelope Reserve, Intangible Cultural Heritage, Beijing-Tianjin-Hebei Integration, China-Europe Trains and other exciting new terms, all leading us to a new era of scientific research results and beautiful pictures of China's beautiful mountains and rivers.
The film also tells the true story of ordinary people. For example, the girl who helped the poor in Tibet, for example, the Ethiopian who set up a shoe factory in Guangzhou, for example, the engineers in their thirties who are working hard for the revitalization of the country's prosperity and strength ...... The predecessors said that "if the youth is strong, China will be strong", and the future belongs to the young, and we need to work hard and forge ahead.
As a young man in the 21st century, in an enterprise that has gone through 60 years, we all need to keep pace with the times, as well as the fighting spirit that never gives up and the creativity that dares to think and fight. I remember there is a saying in Wu Xiaobo's "Thirty Years of Agitating": When this era comes, everything grows wantonly, and dust and dawn rise. Rivers converge into rivers, nameless hills rise into peaks, and heaven and earth are extremely open for a while. Therefore, a bright future will be created by us together. Challenges and opportunities are waiting ahead, waiting for the brave to unveil the veil. The truly powerful person is everyone who sticks to his job and silently contributes value. (Hu Huihua)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31